Cardiovascular and kidney outcomes of linagliptin treatment in older people with type 2 diabetes and established cardiovascular disease and/or kidney disease: A prespecified subgroup analysis of the randomized, placebo‐controlled CARMELINA® trial

AIMS: In CARMELINA®, linagliptin demonstrated cardiovascular and renal safety in patients with type 2 diabetes (T2D) with high renal and cardiovascular disease (CVD) risk. We investigated safety and efficacy of this dipeptidyl peptidase‐4 inhibitor in older participants. MATERIALS AND METHODS: Subje...

Cur síos iomlán

Na minha lista:
Sonraí Bibleagrafaíochta
Foilsithe in:Diabetes Obes Metab
Main Authors: Cooper, Mark E., Rosenstock, Julio, Kadowaki, Takashi, Seino, Yutaka, Wanner, Christoph, Schnaidt, Sven, Clark, Douglas, Johansen, Odd Erik
Formáid: Artigo
Teanga:Inglês
Foilsithe: Blackwell Publishing Ltd 2020
Ábhair:
Original Articles
Rochtain Ar Líne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7317902/
https://ncbi.nlm.nih.gov/pubmed/32037653
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.13995
Clibeanna: Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!

Míreanna Comhchosúla